***PLEASE NOTE: Guidance is being issued by SPS recommending extended monitoring intervals for medication issued under a shared-care agreement during the COVID-19 NHS response - MLCSU reviewed and locally adapted versions of this guidance can be accessed here: MLCSU Central COVID-19 resource page. Please check back regularly for updates***
**Please note — For Blackpool, Fylde & Wyre CCG DMARD Shared Care Guidelines please use the versions available on the CCG website
Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine - For Attention Deficit Hyperactivity Disorder in adults aged over 17 years and in children and adolescents aged 6 to 17 years
Guanfacine - For Attention Deficit Hyperactivity Disorder in children and adolescents aged 6 to 17 years
Amisulpride, Aripiprazole, Olanzapine, Quetiapine, Oral Risperidone
This shared prescribing guideline for the second-generation antipsychotic medications listed above has been developed with due consideration to the appropriate NICE Clinical Guidelines (CG) e.g. Bipolar Disorder (CG185), Psychosis and Schizophrenia in Children and Young People (CG155), Psychosis and Schizophrenia in Adults (CG178), Schizophrenia- Aripiprazole (TA213), Bipolar Disorder- Adolescents (TA292).
Please note: Morecambe Bay CCG has now adopted this Shared-care guideline for all areas, including South Cumbria.
***NICE TA 597 has been withdrawn following an update of the SPC*** FURTHER DETAIL TO FOLLOW AS IT BECOMES AVAILABLE
TO BE DISCUSSED AT THE DECEMBER 2021 LSCMMG
Denosumab 60mg injection - Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of bone loss
associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture
- In the management of acute mania or hypomanic episodes
- In the management of episodes of recurrent depressive disorders where treatment with other antidepressants has been unsuccessful
- In the prophylaxis against bipolar affective disorders
- Control of aggressive behaviours of intentional self-harm.
Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic
arthritis, severe psoriatic arthritis, mild to moderate Crohn’s disease
Unlicensed: Severe Eczema, Lichen Planus, Felty’s syndrome, severe Crohn’s disease
N.B. Not all brands/formulations are licensed for all indications – please refer to individual SPCs
This protocol only applies to the unlicensed indications listed below. Transplant protocols should be followed for licensed indications.
Unlicensed: Severe rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, connective tissue diseases with severe / organ-threatening manifestations, interstitial lung disease (not to be used in idiopathic pulmonary fibrosis IPF), vasculitidies, as maintenance post cyclophosphamide in patients for whom azathioprine is contra-indicated or is inappropriate.
To extend life or the time to mechanical ventilation for adult patients with amyotrophic lateral sclerosis (ALS) 1,2, variant of Motor Neurone Disease (MND). Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other forms of MND. Riluzole should only be initiated by a neurological specialist with expertise in the management of MND (as per NICE TA 20, 2001)
It is expected that most patients will be managed by secondary care however this guideline is those patients who need to be managed in community
Licensed – Active, progressive rheumatoid arthritis, progressive juvenile chronic arthritis especially if polyarticular or seropositive.
Unlicensed – skin diseases including pemphigus
This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.